The Effect of Amantadine on Corneal Endothelium in Subjects with Parkinson's Disease

Ki Cheol Chang, Jin Ho Jeong, Mee Kum Kim, Won Ryang Wee, Jin Hak Lee, Beom Seok Jeon

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Objective: To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Design: Cross-sectional study. Participants: A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Methods: Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Main Outcome Measures: Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. Results: The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89, P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87, P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group. Conclusions: Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish
Pages (from-to)1214-1219
Number of pages6
JournalOphthalmology
Volume117
Issue number6
DOIs
StatePublished - 1 Jun 2010

Cite this